Welcome to our dedicated page for AbbVie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on AbbVie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (ABBV) declared a quarterly cash dividend of $1.73 per share, payable on November 16, 2026, to shareholders of record as of October 15, 2026.
The company states that since its 2013 inception it has increased its dividend by more than 330% and is included in the S&P Dividend Aristocrats Index, which tracks companies that have raised dividends annually for at least 25 consecutive years.
AbbVie (ABBV) reported positive Phase 3 LUNA trial topline results for atogepant in menstrual migraine on September 10, 2026.
The randomized, double-blind, placebo-controlled study in 468 adult women evaluated atogepant taken for seven consecutive days starting three days before menses, over three menstrual cycles. Atogepant met the primary endpoint, reducing migraine days during the perimenstrual period by an average of 1.20 days versus 0.40 days with placebo, for 0.80 fewer migraine days versus placebo (p<0.0001). All eight ranked secondary endpoints, covering headache burden, acute medication use, functional disability, cognitive function and responder outcomes, also showed statistically significant improvements versus placebo (p<0.0001).
Safety findings were consistent with the known safety profile of atogepant, with no new safety signals observed. AbbVie plans to submit LUNA data to health authorities worldwide and present the results at future medical congresses.
AbbVie (ABBV) reported positive topline Phase 3 CERVINO results showing investigational BCMA x CD3 bispecific etentamig improved objective response rate and progression-free survival versus standard available therapies in triple-class exposed relapsed/refractory multiple myeloma.
Among 393 patients with a median of three prior treatment lines and 11.4 months median follow-up, etentamig achieved a significantly higher ORR of 74.0% versus 45.7% with investigator’s choice therapies and improved PFS with a hazard ratio of 0.40, with benefit seen across all pre-specified subgroups. Twelve‑month overall survival was 87.9% with etentamig versus 72.0% with standard therapies (HR 0.48), although the prespecified OS efficacy boundary was not crossed. Safety with a single step-up dose and monthly dosing showed low, mostly grade 1 cytokine release syndrome (28.3% CRS, no grade ≥3) and low treatment-emergent adverse event discontinuations (3.6% vs 9.6%). The Independent Data Monitoring Committee recommended unblinding based on the significant benefit, and AbbVie plans discussions with global regulators.
AbbVie (ABBV) completed its acquisition of Apogee Therapeutics (APGE), paying $135.11 in cash per share, implying equity value of approximately $10.9 billion as of September 3, 2026.
The acquisition adds Apogee's immunology pipeline, led by zumilokibart, a late-stage, half-life extended IL-13 monoclonal antibody in development for atopic dermatitis and other inflammatory diseases. In a Phase 2 trial in atopic dermatitis, roughly two-thirds of patients on zumilokibart achieved significant skin clearance at 16 weeks, with improved itch and disease control, and data support quarterly or twice-yearly dosing with a favorable safety profile.
The deal also brings APG273, a long-acting combination of zumilokibart and APG333 targeting IL-13 and TSLP for asthma. AbbVie expects EPS dilution of $0.14 in 2026 and about $0.46 in 2027, but reaffirmed 2026 full-year adjusted diluted EPS guidance of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88.
AbbVie (ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, including a management fireside chat.
The discussion is scheduled for 9:00 a.m. Central time and will be available via live audio webcast on AbbVie’s Investor Relations website, with an archived replay accessible later that day.
AbbVie (ABBV), through its Allergan Aesthetics unit, released the global Layered Beauty: The New Aesthetic Mindset report, based on research among more than 12,000 beauty-involved consumers across nine markets. The report examines evolving attitudes toward beauty, aging and aesthetic treatments.
Findings highlight a shift from one-time procedures to personalized, long-term, multimodal treatment plans, growing focus on skin quality as the base of aesthetic care, and continued reliance on healthcare provider expertise. Regional differences in beauty ideals underscore the need for localized approaches. The full report is available at global.allerganaesthetics.com/layered-beauty.
AbbVie (NYSE: ABBV), via its Allergan Aesthetics unit, expanded the SkinMedica regenerative skincare line with the launch of Barrier Calming Cream, a restorative moisturizer aimed at soothing skin and supporting the skin barrier. Clinical testing showed a 30% reduction in skin dryness after two weeks. The cream uses a Calcium Strengthening Complex and Botanical Calming Complex to promote barrier resilience, calm visible redness, and improve hydration.
SkinMedica also introduced HA5 Hydra Collagen Facial Mist with vegan collagen and five forms of hyaluronic acid, which immediately increased skin hydration by 31% and improved dryness by 62% in testing. The cream ($140) and mist ($58) are available via SkinMedica.com and select medical providers. AbbVie notes SkinMedica products are cosmetics, not FDA-approved drugs.
AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Company management will join a fireside chat at 9:15 a.m. Central time, with a live audio webcast and same-day archive available via AbbVie's investor relations website.
AbbVie (NYSE: ABBV) has submitted a regulatory application to the European Medicines Agency (EMA) for SKYRIZI (risankizumab) subcutaneous (SC) induction to treat adult patients with moderately to severely active Crohn's disease. The filing is supported by positive Phase 3 AFFIRM study data evaluating SC induction efficacy and safety.
SKYRIZI is already approved in the EU for intravenous (IV) induction and SC maintenance in Crohn's disease, as well as for plaque psoriasis, psoriatic arthritis and ulcerative colitis. If approved, Crohn's patients could choose either SC injection or IV infusion for induction, followed by SC maintenance every eight weeks.
AbbVie (NYSE: ABBV) will present extensive new data from its lung cancer portfolio at the 2026 World Conference on Lung Cancer, spanning NSCLC and SCLC.
Key highlights include Phase 1b results for ABBV-1480 (RC148) plus platinum chemotherapy in first-line advanced NSCLC, showing an objective response rate of 90.0% in squamous (27/30) and 75.9% in non-squamous (22/29) disease at the 10 mg/kg dose, which was selected as the recommended Phase 3 dose. Additional updates cover the telisotuzumab adizutecan (Temab-A) antibody-drug conjugate in first-line non-squamous and EGFR-mutated NSCLC, and ABBV-706 in relapsed/refractory SCLC, including new safety analyses from 240 patients and real-world data supporting SEZ6 as a potential target.